SCHEDULE: T. Rowe Price Discloses Stake in Soleno Therapeutics

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 2.0% of Soleno Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, indicating their beneficial ownership of Soleno Therapeutics Inc. common stock.
• As of March 31, 2026, T. Rowe Price Associates, Inc. beneficially owns 1,025,868 shares of Soleno Therapeutics Inc. common stock.
• This represents 2.0% of the total class of securities.
• The filing is made under Rule 13d-1(b), classifying T. Rowe Price Associates, Inc. as an investment adviser.
• The company certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It indicates institutional interest but does not provide operational or financial performance data for Soleno Therapeutics Inc. itself.

Positives

• T. Rowe Price Associates, Inc., a significant investment management firm, has taken a position in Soleno Therapeutics Inc., which could signal confidence in the company's prospects.
• The filing indicates a passive investment approach, not aimed at influencing control, which is typical for institutional investors managing client assets.

Negatives

• The filing does not contain any negative financial results or operational challenges for Soleno Therapeutics Inc. itself, as it is a disclosure of ownership by an external entity.

Risks

• The primary risk associated with this filing is the potential for T. Rowe Price Associates, Inc. to change its investment strategy and divest its shares, which could impact Soleno Therapeutics Inc.'s stock price.
• As with any investment, there is the inherent risk that Soleno Therapeutics Inc. may not perform as expected, leading to a decrease in the value of the shares held by T. Rowe Price Associates, Inc.

Future Outlook

The filing itself does not provide forward-looking statements or guidance for Soleno Therapeutics Inc. It is a disclosure of ownership by T. Rowe Price Associates, Inc.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that the acquisition of a 2.0% stake by a major asset manager like T. Rowe Price Associates, Inc. in a biotechnology company like Soleno Therapeutics Inc. is a common occurrence in the sector. Such filings often indicate institutional interest and can precede further developments or analyst coverage.

Stakeholder Impact

• Shareholders: May view the increased institutional interest positively, potentially leading to increased trading volume or future price appreciation. However, a large divestment by T. Rowe Price could negatively impact the stock price.
• Management of Soleno Therapeutics Inc.: May see this as validation of their strategy, but also need to be mindful of the passive investor's potential influence if the stake were to grow significantly or if the investor decided to engage more actively.

Next Steps

• Monitor future filings by T. Rowe Price Associates, Inc. for any changes in their stake in Soleno Therapeutics Inc.
• Observe Soleno Therapeutics Inc.'s operational and financial performance for potential impact from institutional investor interest.

Key Dates

Keywords

Soleno Therapeutics, T. Rowe Price Associates, Schedule 13G, SEC Filing, Beneficial Ownership, Investment Management, Common Stock, Institutional Investor